ArticleEuropean journal of clinical pharmacology2009
Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
Article in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of CYP2C19 genetic polymorphisms on the cure rates ofFrontiers in pharmacology · 2022Pooled it
- Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.Advances in therapy · 2021Trial
- Pharmacokinetics and bioequivalence evaluation of omeprazole and sodium bicarbonate dry suspensions in healthy Chinese volunteers.Scientific reports · 2023Article
- A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough.Journal of thoracic disease · 2016Article
- Refractory chronic cough due to gastroesophageal reflux: Definition, mechanism and management.World journal of methodology · 2015Review
- PK/PD modeling of rabeprazole in CYP2C19 genotypes: consideration of the influence of thio-ether metabolite, CYP3A4, accumulation and CYP2D6 polymorphism may help to better develop and validate the model.European journal of clinical pharmacology · 2011Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
18958459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.